Mark Pass, MD
Geriatric Medicine · Manalapan, NJNPI 1437156288
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $897 of the $1,061 with a category attached, or 84.6%. It is spread thinly across 16 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $434 and has fallen 70.5% since, to $128 in 2025.
Across 33 payments — averaging $32.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$148
- Astellas Pharma US Inc$140
- Axsome Therapeutics, Inc.$124
- Lilly USA, LLC$111
- Otsuka America Pharmaceutical, Inc.$109
- Verrica Pharmaceuticals Inc.$98
- plus $330 from 10 others
What the payments were for
- Food & beverage$89785%
- Education$16315%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 7 | $148 |
| Astellas Pharma US Inc | 2 | $140 |
| Axsome Therapeutics, Inc. | 1 | $124 |
| Lilly USA, LLC | 1 | $111 |
| Otsuka America Pharmaceutical, Inc. | 1 | $109 |
| Verrica Pharmaceuticals Inc. | 1 | $98 |
| Boston Scientific | 1 | $64 |
| Johnson & Johnson | 4 | $56 |
| GSK | 4 | $54 |
| Paratek Pharmaceuticals, Inc. | 3 | $48 |
| Sunovion Pharmaceuticals Inc. | 3 | $35 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $23 |
| Acadia Pharmaceuticals Inc | 1 | $15 |
| Bardy Diagnostics, Inc. | 1 | $13 |
| AbbVie | 1 | $11 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,061 in reported general payments places this provider in the 65th percentile of 165 geriatric medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,374 | $606,670 |
| XareltoRivaroxaban | 533 | $228,429 |
| JanuviaSitagliptin Phosphate | 206 | $127,853 |
| MyrbetriqMirabegron | 271 | $115,336 |
| MounjaroTirzepatide | 96 | $104,895 |
| OzempicSemaglutide | 84 | $98,186 |
| JardianceEmpagliflozin | 150 | $68,994 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 85 | $68,803 |
| RybelsusSemaglutide | 58 | $62,557 |
| EntrestoSacubitril/Valsartan | 100 | $57,396 |
| FarxigaDapagliflozin Propanediol | 94 | $56,135 |
| TrulicityDulaglutide | 74 | $56,074 |
| Breo ElliptaFluticasone/Vilanterol | 115 | $53,334 |
| ZenpepLipase/Protease/Amylase | 60 | $52,331 |
| NuedextaDextromethorphan Hbr/Quinidine | 38 | $43,685 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto, Prezcobix, Procrit | $56 | $276,594587 claims |
| Lilly USA, LLCMounjaro, Trulicity | $111 | $160,969170 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $54 | $144,635244 claims |
| Astellas Pharma US IncMyrbetriq | $140 | $115,336271 claims |
| NovartisEntresto | $148 | $57,396100 claims |
| AbbVieVraylar, Creon | $11 | $54,61940 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $11 | $31,02724 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $109 | $22,35418 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $35 | $19,84328 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 165 geriatric medicine providers in New Jersey.
Other geriatric medicine in Manalapan
- Sajida MokhashiManalapan$1K
- Albert RiddleHaworth$524K
- Gamil MakarClifton$82K
- Joshua Shua HaimManchester$45K
- Pradip ShahWest Caldwell$27K
- Gregorio GuillenPerth Amboy$8K
- Ketankumar VaidyaEdison$8K
- Cheng-An MaoClifton$8K
- Theresa RedlingLivingston$7K
- Sarita RastogiHackensack$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.